Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s Avastin launched for ovarian cancer in UK

Roche’s Avastin launched for ovarian cancer in UK

19th January 2012

Roche has announced the UK launch of its multipurpose oncology therapy Avastin in a new specification for ovarian cancer patients.

The drug is now available for the treatment of advanced ovarian cancer in combination with standard chemotherapy, following approval from the European Medicines Agency.

Avastin's safety and efficacy against the disease have been proven in a pair of pivotal phase III clinical trials, making it the first new drug that has been shown to be effective for this patient population in 15 years.

The drug is available to English patients via the Cancer Drugs Fund, while Scottish, Northern Irish and Welsh clinicians can make individual funding requests for the product.

Dr Timothy Perren, consultant medical oncologist at St James' University Hospital, said: "Ovarian cancer currently has the worst outcomes of all gynaecological cancers and halting disease progression for six months is an important step forward in treating this condition."

This represents the fifth tumour type for which Avastin has been approved in Europe.ADNFCR-8000103-ID-801268902-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.